Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Remember that open communication with healthcare providers is vital to ensure the safe and effective use of combination therapies for weight loss
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
Neither timing has demonstrated superiority in clinical data
These came from different trials, with different durations, dose-titration schedules, and patient populations they were not compared head-to-head
individual experience varies considerably
GLP-1 Drugs for Weight Loss and Diabetes What You Need to Know (And What the Ads Won't Tell You) If you've seen Ozempic ads on TV, heard about it from a friend, or talked to your doctor about it, you're not alone
US$ 27.73
US$ 23.66
US$ 20.92
US$ 24.43
